Carisma nominates first in vivo CAR-M candidate under Moderna collab; $2M milestone triggered

Carisma Therapeutics Inc.

Development candidate targets Glypican-3 for solid tumors, including hepatocellular carcinoma (HCC).
Nomination triggers a $2M milestone payment to Carisma from Moderna.
Candidate uses Carisma's CAR-M expertise and Moderna's mRNA/LNP platform for in vivo cell therapy.
Moderna leads development and commercialization; four undisclosed oncology targets also nominated.
Pre-clinical data showed successful in vivo creation of CAR-M redirecting myeloid cells against cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.